Dyne Therapeutics, Inc. Total Liabilities
Dyne Therapeutics, Inc. (DYN) had Total Liabilities of $291.86 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-07-29
- 2026-06-30: Liabilities $291.86M.
- 2026-03-31: Liabilities $214.90M.
- 2025-12-31: Liabilities $214.83M.
- 2025-09-30: Liabilities $175.28M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $291.86M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $214.90M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $214.83M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $175.28M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $157.55M 10-Q · filed 2025-07-28 |
| 2025-03-31 | $52.10M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $61.40M 10-K · filed 2026-03-02 |
| 2024-09-30 | $63.30M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $50.69M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $44.22M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $73.79M 10-K · filed 2025-02-27 |
| 2023-09-30 | $53.21M 10-Q · filed 2023-10-30 |
| 2023-06-30 | $44.54M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $46.71M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $53.96M 10-K · filed 2024-03-05 |
| 2022-09-30 | $49.94M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $52.97M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $51.30M 10-Q · filed 2022-05-02 |
| 2021-12-31 | $57.47M 10-K · filed 2023-03-02 |
| 2021-09-30 | $52.76M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $14.55M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $13.45M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $10.97M 10-K · filed 2022-03-10 |
| 2020-09-30 | $14.63M 10-Q · filed 2020-11-05 |
| 2019-12-31 | $2.40M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |